In the head-to-head phase 3 TRANSCEND-T2D-2 trial, the investigational triple agonist achieved superior HbA1c reduction and more than double the weight loss of semaglutide 2mg at week 80.
Total naloxone administrations and layperson-administered naloxone administration were below projected levels.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results